Vyepti® (eptinezumab) is a quarterly intravenous treatment designed to prevent migraines before they begin. Unlike daily medications or monthly injections, Vyepti is administered only four times per year and targets CGRP, a key migraine signaling molecule. Learn how this innovative therapy works, who may qualify, what side effects to consider, and the insurance steps often required before treatment can begin. This guide reviews the benefits, risks, and practical consideration

Introducing a marvelous product that provides substantial control to the hot flashes, sleeplessness, mood swings associated with menopause.